Cutting down ultra-processed foods for people at high cancer risk
Official title: Impact of a Mixed Intervention Aiming to Decrease the Consumption of Ultra-processed Foods on the Global Diet Quality in Individuals at High Risk of Cancer
Run by Gustave Roussy, Cancer Campus, Grand Paris · NCT07436312 · Data updated 2026-11-12
This project tests whether using the Open Food Facts smartphone app alongside nutrition education helps adults at high risk of cancer eat fewer ultra-processed foods.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 170 (estimated) |
| Sponsor | Gustave Roussy, Cancer Campus, Grand Paris Academic / other |
| Locations | 3 sites (Avignon and 2 other locations) |
| Status | Recruiting |
| Started | May 4, 2026 |
| Main results expected | September 2027 |
| Study ends | March 2028 |
| Registry record updated | May 8, 2026 |
| Trial ID | NCT07436312 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults over 18 enrolled in the Interception program who are at increased cancer risk, have a baseline WCRF score ≤ 5, speak French, own a smartphone, and agree to complete study questionnaires.
✕Probably not a fit
People who already follow strong cancer-prevention diets (WCRF > 5), cannot use a smartphone, have cognitive or psychiatric conditions, or are under legal guardianship are unlikely to benefit or are excluded.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
The U-TRANS program enrolls adults at increased cancer risk with a low baseline WCRF score and provides a standard nutrition education workshop; participants in the intervention arm also receive training and support to use the Open Food Facts app to identify and avoid ultra-processed foods. Dietary intake and UPF exposure are measured at baseline and after 12 weeks using an adapted food frequency questionnaire and WCRF scoring. The study tracks frequency of app use and analyzes determinants of behavior change to identify who benefits most. Outcomes will compare changes in UPF consumption and overall diet quality between the education-only and app-supported arms.
Why it matters
Potential benefit: If successful, the intervention could help people at high cancer risk improve overall diet quality and potentially lower their future cancer risk by reducing ultra-processed food intake.
How similar studies have gone: Previous digital nutrition and food-labeling app studies have shown modest improvements in food choices, but using Open Food Facts specifically to reduce ultra-processed food intake is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Age \> 18 years, 2. Individuals at increased risk of different cancers as defined within the Interception program, 3. With a baseline WCRF score ≤ 5 at entry in the Interception program, 4. Agreeing to participate and who have given their written agreement for the study, 5. Agreeing to fill in the questionnaires on the dedicated platform for the duration of the study, 6. Participant have and accept to use their smartphone, 7. All participants must understand spoken and written French language Exclusion Criteria: 1. Psychiatric disorders or cognitive impairments precluding participation, 2. Patient under guardianship or deprived of his liberty by a judicial or administrative decision or incapable of giving its consent.
Where it's running
-
Eugène Marquis
Rennes, France Recruiting -
Gustave Roussy
Villejuif, France Recruiting -
Institut Sainte Catherine
Avignon, France Not yet recruiting
Study contacts
- Study coordinator: Bruno Raynard, MD
- Email: bruno.raynard@gustaveroussy.fr
- Phone: +33 (0) 1 42 11 42 11
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Treatment using CEA-targeted CAR-T cells for advanced solid tumors
This study is testing a new type of immune therapy using CAR-T cells to see if it can help people with advanced solid tumors that have a specific marker called CEA.
-
Developing a liquid biopsy protocol for cancer research at Princess Margaret
This study is trying to create a simple way to collect blood samples from cancer patients to see if analyzing certain molecules in their blood can help doctors understand their cancer better and track how it changes over time.
-
A resource for collecting cancer data and biospecimens
This study is creating a resource to collect health information and samples from cancer patients and healthy individuals to help improve cancer prevention and treatment strategies.
-
INSPIRE: Putting patient-reported info into multidisciplinary tumor boards
This study tests whether adding electronic patient-reported outcomes to tumor board discussions can help guide treatment decisions for women with breast, gynecologic, pancreatic cancers and related cancers.
-
Digital app to support oncologist‑initiated genetic testing
This project tests a digital app (GA‑Mainstream) to help oncologists offer germline genetic testing to adults with breast, prostate, colon, or other GI cancers.
-
Axelopran for adults with advanced breast, lung, pancreas, or prostate cancer who take opioids
This trial will test whether taking axelopran can slow tumor progression, help bowel problems, and reduce inflammation in adults with advanced breast, lung, pancreas, or prostate cancer who are using opioid pain medicines.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.